According to Thermo Fisher's 15-minute chart, the MACD and KDJ indicators have both triggered "death crosses" at 10:00 on September 23, 2025. This indicates that the stock price has the potential to continue declining, as the momentum of the stock price is shifting towards the downside and could potentially lead to further decreases.
On September 23, 2025, Thermo Fisher Scientific Inc. (NYSE: TMO) experienced a significant drop in its stock price, triggered by the "death cross" signals from the MACD and KDJ indicators on its 15-minute chart. This technical indicator suggests a potential continuation of the stock's downward trend, as the momentum is shifting towards the downside
Pictet North America Advisors SA Trims Stock Position in Thermo Fisher Scientific Inc. $TMO[1].
The stock price decreased by 1.1% to $474.54, with a market capitalization of $179.19 billion and a price-to-earnings ratio of 27.45. This decline comes amidst several institutional adjustments in the company's stock holdings. Pictet North America Advisors SA reduced its holdings by 15.1%, owning 7,630 shares valued at approximately $3.09 million
Pictet North America Advisors SA Trims Stock Position in Thermo Fisher Scientific Inc. $TMO[1].
Other notable institutional changes include Mondrian Investment Partners LTD, which increased its holdings by 146.1%, now owning 214,506 shares valued at $106,738,000, and Foresight Group Ltd Liability Partnership, which boosted its holdings by 3,242.7%, owning 58,497 shares valued at $29,113,000
Pictet North America Advisors SA Trims Stock Position in Thermo Fisher Scientific Inc. $TMO[1]. Meanwhile, Park Avenue Securities LLC cut its position by 22.2%, holding 11,926 shares valued at $4,836,000
Park Avenue Securities LLC Sells 3,405 Shares of Thermo Fisher Scientific Inc. $TMO[2].
These changes reflect a broader trend in institutional sentiment towards Thermo Fisher Scientific. Despite recent earnings results that exceeded analyst expectations, with earnings per share (EPS) of $5.36 for the quarter, the company's guidance for the third quarter of 2025 and fiscal year 2025 was met with cautious optimism. Analysts have set new price targets, with a mix of "Buy," "Hold," and "Outperform" ratings, indicating a varied outlook on the stock's future performance
Pictet North America Advisors SA Trims Stock Position in Thermo Fisher Scientific Inc. $TMO[1].
Insider trading also played a role in the recent stock movements. Executive Vice President Gianluca Pettiti sold 400 shares, and CEO Marc N. Casper sold 400 shares, resulting in a combined reduction of 0.33% of the stock owned by insiders
Pictet North America Advisors SA Trims Stock Position in Thermo Fisher Scientific Inc. $TMO[1].
Investors should closely monitor these developments and consider the potential implications of the "death cross" signals and institutional adjustments on Thermo Fisher Scientific's stock price. The company's ongoing financial performance and strategic initiatives will be crucial in determining its future trajectory.
Comments
No comments yet